Pulmonx (LUNG) Projected to Post Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $22.03 million for the quarter.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.01. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The firm had revenue of $22.54 million for the quarter, compared to analysts' expectations of $22.03 million. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Price Performance

LUNG stock remained flat at $3.77 on Friday. The company had a trading volume of 902,554 shares, compared to its average volume of 315,649. The firm's 50 day simple moving average is $6.43 and its two-hundred day simple moving average is $6.53. The company has a market cap of $151.73 million, a P/E ratio of -2.62 and a beta of 0.61. Pulmonx has a one year low of $3.61 and a one year high of $10.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70.

Analyst Ratings Changes

Several equities analysts have recently issued reports on LUNG shares. Piper Sandler reaffirmed an "overweight" rating and issued a $9.00 price target (down previously from $10.00) on shares of Pulmonx in a research report on Thursday. Jefferies Financial Group assumed coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a "buy" rating on the stock. Morgan Stanley started coverage on shares of Pulmonx in a research report on Monday, March 10th. They set an "equal weight" rating for the company. Citigroup initiated coverage on Pulmonx in a research report on Monday, March 10th. They issued a "buy" rating on the stock. Finally, D. Boral Capital restated a "buy" rating and issued a $17.00 price target on shares of Pulmonx in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $12.07.

Insider Buying and Selling

In other Pulmonx news, Director Glendon E. French III sold 55,453 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $8.28, for a total value of $459,150.84. Following the completion of the sale, the director now owns 1,011,974 shares in the company, valued at $8,379,144.72. This represents a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Geoffrey Beran Rose sold 5,779 shares of Pulmonx stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.13, for a total value of $41,204.27. Following the transaction, the insider now directly owns 285,278 shares in the company, valued at approximately $2,034,032.14. The trade was a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 145,660 shares of company stock valued at $1,128,484 over the last 90 days. Company insiders own 6.80% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.